Keywords
How to Cite
Abstract
Ko’plab revmatoid artritli bemorlarda COVID-19 pandemiyasidan so’ng kasallikni klinik kechishining aktivlashishi, yangi asoratlar va aksariyat bemorlarda koviddan keying holat kuzatildi. Ushbu maqolada COVID-19 pandemiyasidan so’ng 3 yil davomidagi xalqaro ilmiy izlanishlarda aniqlangan COVID-19 revmatoid artrit klinik kechishiga ta’siri va davolanishdagi natijalari o’rganiladi.
References
Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature.2020;584(7821):430-436. doi: 10.1038/s41586-020-2521-4
Liu M, Gao Y, Zhang Y, Shi S, Chen Y, Tian J. The association between severe or dead COVID-19 and autoimmune diseases: A systematic review and meta-analysis. J Infect. 2020;81(3):e93-e95. doi: 10.1016/j.jinf.2020.05.065
Sparks JA. Rheumatoid arthritis. Ann Intern Med 2019; 170:ITC1–ITC16.
Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis 2019; 78:1463–1471.
Белов БС, Лила АМ. COVID-19 и ревматология: год спустя. Научно-практическая ревматология. 2021;59(1):31-36. [Belov BS, Lila AM. COVID-19 and rheumatology: A year later. Nauchno-Prak-ticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(1):31-36 (In Russ.)]. doi: 10.47360/1995-4484-2021-31-36
Hu B, Huang S, Yin L (2021). The cytokine storm and COVID-19. J Med Virol, 93:250-256. [3] Rodriguez-Morales AJ, Cardona-Ospina JA, GutiérrezOcampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. (2020). Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis, 34:101623.
CURRENT OPINION in rheumatology/ Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic / Volume 35 Number 3 May 2023 / Alessandra Zaccardellia , Zachary S. Wallaceb,c,d and Jeffrey A. Sparksd,e/
Harrison AG, Lin T, Wang P (2020). Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends Immunol, 41:1100-1115.
Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. (2018). Rheumatoid arthritis. Nat Rev Dis Primers, 4:18001. [5] Scherer HU, Hupl T, Burmester GR (2020). The etiology of rheumatoid arthritis. Journal of Autoimmunity, 110:102400.
Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE (2002). Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum, 46:2287-2293.
Mehta B, Pedro S, Ozen G, Kalil A, Wolfe F, Mikuls T, et al. (2019). Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open, 5:e000935.
England BR, Roul P, Yang Y, Kalil AC, Michaud K, Thiele GM, et al. (2021). Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At-Risk Individuals. Arthritis Rheumatol, 73:2179-2188
Cobb S, Anderson F, Bauer W (1953). Length of life and cause of death in rheumatoid arthritis. New England Journal of Medicine, 249:553-556.
Uddin J, Kraus AS, Kelly HG (1970). Survivorship and death in rheumatoid arthritis. Arthritis Rheum, 13:125- 130.
Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ (2003). National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol, 30:958-965.
Franklin J, Lunt M, Bunn D, Symmons D, Silman A (2007). Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis, 66:308-312
Maddur MS, Vani J, Lacroix-Desmazes S, Kaveri S, Bayry J (2010). Autoimmunity as a predisposition for infectious diseases. PLoS Pathog, 6:e1001077
Grainger R, Kim AHJ, Conway R, Yazdany J, Robinson PC (2022). COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nat Rev Rheumatol, 18:191-204
Schett G, Manger B, Simon D, Caporali R (2020). COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol, 16:465-470.
Blumentals WA, Arreglado A, Napalkov P, Toovey S (2012). Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord, 13:158-167.
К.Ю.Картышева, Т.И.Оконенко, Е.Е.Румянцев, А.К.Искандарян, С.В.Мербах/ ЗНАЧЕНИЕ ГЕННО-ИНЖЕНЕРНЫХ ПРЕПАРАТОВ В ТЕРАПИИ НОВОЙ КОРОНАВИРУСНОЙ ИНФЕКЦИИ И РЕВМАТОИДНОГО АРТРИТА/ 2022 ВЕСТНИК НОВГОРОДСКОГО ГОСУДАРСТВЕННОГО УНИВЕРСИТЕТА №2 стр.76-79.
Galarza-Delgado D.Б. et al. Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy // Clin Rheumatol. 2021. Vol. 40, № 3. P. 1197-1199
Loarce-Martos J, Garcнa-Fernбndez A, Lуpez-Gutiйrrez F, Garcнa-Garcнa V, Calvo-Sanz L, Del Bosque-Granero I, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: A descriptive study. Rheumatol Int. 2020;40(12):2015-2021. doi:10.1007/s00296-020-04699-x
Dernoncourt A, Schmidt J, Duhaut P, Liabeuf S, GrasChampel V, Masmoudi K, et al. COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database. Fundam Clin Pharmacol. 2022;36(1):199-209. doi: 10.1111/fcp.12695.
Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al.; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871.
Jiang Y, Zhao T, Zhou X, Xiang Y, Gutierrez-Castrellon P, Ma X. Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions. MedComm. 2022;3(3):e154. doi: 10.1002/mco2.154
Lin YJ, Anzaghe M, Schülke S (2020). Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. Cells, 9:880-922.
Listing J, Gerhold K, Zink A (2013). The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford), 52:53-61.
Harrison C (2020). Focus shifts to antibody cocktails for COVID-19 cytokine storm. Nat Biotechnol, 38:905-908.
Simon D, Tascilar K, Krönke G, Kleyer A, Zaiss MM, Heppt F, et al. (2020). Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nat Commun, 11:3774-3780.
Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN (2020). Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs, 80:1267-1292.
Wang Y, Jiang W, He Q, Wang C, Tong Q (2020). Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. Cold Spring Harbor Laboratory Press. [113] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. (2020). Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med, 180:934-943.
Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. (2020). Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis, 79:859-866.
Tang J (2022). COVID-19 Pandemic and Osteoporosis in Elderly Patients. Aging Dis, 13:960-969.
Favalli EG, Bugatti S, Klersy C, Biggioggero M, Rossi S, De Lucia O, et al. (2020). Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. Arthritis Res Ther, 22:290-301.
Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. (2015). Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet, 386:258-265.
Jie Xiao1,2#, Chaoyi Liang1,2#, Lizeai Zhang2# , Jinling Li2,3*, Sijia Liu1,2*.The Intersection of COVID-19 and Rheumatoid Arthritis: Shared Mechanisms, Treatment Challenges, and Potential Therapeutic Approaches. Aging and Desease,Volume 14, Number 4; 1196-1213, August 2023
Schett G, Manger B, Simon D, Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol. 2020;16(8):465-470. doi: 10.1038/s41584-020-0451-z